Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abnova (Taiwan)TPE:4133 -0.48%77 EV-to-FCF is 47.66 as of Aug. 22, 2026, which is 125% above its 10-year median of 21.15. GuruFocus rates TPE:4133 with a GF Score™ of 77/100 and a GF Value™ of NT$27.85 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 321 Biotechnology companies, Abnova (Taiwan) ranks worse than 76.01% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Abnova (Taiwan)'s Enterprise Value is NT$880.1 Mil.
Abnova (Taiwan)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was NT$18.5 Mil. Therefore, Abnova (Taiwan)'s EV-to-FCF for today is 47.66.
The historical rank and industry rank for Abnova (Taiwan)'s EV-to-FCF or its related term are showing as below:
TPE:4133'
s EV-to-FCF Range Over the Past 10 Years
Min: -309.23 Med: 21.15 Max: 378.49
Current: 47.66
During the past 13 years, the highest EV-to-FCF of Abnova (Taiwan) was 378.49. The lowest was -309.23. And the median was 21.15.
TPE:4133's EV-to-FCF is ranked worse than 76.01% of 321
companies
in the Biotechnology industry
Industry Median: 16.05
vs TPE:4133: 47.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abnova (Taiwan)'s PE Ratio (TTM) for today is calculated as:
Abnova (Taiwan)'s share price for today is NT$20.75.
Abnova (Taiwan)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Abnova (Taiwan) EV-to-FCF Related Terms
Abnova (Taiwan) EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s EV-to-FCF falls into.
Abnova (Taiwan)'s current Enterprise Value is NT$880.1 Mil.
Abnova (Taiwan)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$18.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) (TPE:4133) has a EV-to-FCF of 47.66 as of Aug. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abnova (Taiwan) and its competitors. This is 125% above median its historical median of 21.15. According to the industry distribution chart, Abnova (Taiwan) ranks #244 out of 321 companies in the Biotechnology industry, placing it in the top 76%.
Is Abnova (Taiwan)'s EV-to-FCF too high?
Abnova (Taiwan)'s current EV-to-FCF of 47.66 is 125% above median its 10-year median of 21.15. The Biotechnology industry median EV-to-FCF is 16.05. Abnova (Taiwan)'s value of 47.66 is 196.9% above this industry median. Based on the distribution chart, Abnova (Taiwan) ranks #244 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abnova (Taiwan) has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #244 out of 321 companies for EV-to-FCF. This places Abnova (Taiwan) in the lower half of its industry. The industry median EV-to-FCF is 16.05. Abnova (Taiwan)'s value of 47.66 is 196.9% above this benchmark. While the company's 10-year median is 21.15 vs. the industry median of 16.05, Abnova (Taiwan) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.05, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abnova (Taiwan)'s current EV-to-FCF of 47.66 is 196.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Abnova (Taiwan) and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abnova (Taiwan)'s current EV-to-FCF is 47.66, which is 125% above median its own 10-year median of 21.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.85, compared to a current price of NT$20.75 — trading 25.5% below its estimated fair value. The current EV-to-FCF is 47.66, which is 125% above median its 10-year median of 21.15 and 196.9% above the Biotechnology industry median of 16.05. Abnova (Taiwan)'s overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current EV-to-FCF is 47.66 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.75 is trading 25.5% below its estimated GF Value™ of NT$27.85.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
EV-to-FCF: 47.66 (125% above median its 10-year median of 21.15)
GF Value™: NT$27.85 vs. price of NT$20.75 (25.5% below fair value)
Industry Position: 196.9% above the Biotechnology median (#244 of 321)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
77GF Score
Get the complete analysis for TPE:4133
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
